Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Total Liabilities (2020 - 2026)

Rani Therapeutics Holdings' Total Liabilities history spans 7 years, with the latest figure at $16.3 million for Q1 2026.

  • On a quarterly basis, Total Liabilities fell 44.57% to $16.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $16.3 million, a 44.57% decrease, with the full-year FY2025 number at $17.1 million, down 48.38% from a year prior.
  • Total Liabilities came in at $16.3 million for Q1 2026, down from $17.1 million in the prior quarter.
  • The five-year high for Total Liabilities was $39.0 million in Q1 2024, with the low at $4.7 million in Q1 2022.
  • Historically, Total Liabilities has averaged $27.3 million across 5 years, with a median of $32.5 million in 2023.
  • Peak annual rise in Total Liabilities hit 1188.75% in 2022, while the deepest fall reached 96.06% in 2022.
  • Year by year, Total Liabilities stood at $34.0 million in 2022, then decreased by 4.56% to $32.5 million in 2023, then rose by 2.06% to $33.1 million in 2024, then plummeted by 48.38% to $17.1 million in 2025, then dropped by 4.52% to $16.3 million in 2026.
  • Business Quant data shows Total Liabilities for RANI at $16.3 million in Q1 2026, $17.1 million in Q4 2025, and $22.1 million in Q3 2025.